the unmet medical needs of patients in the areas of anti-HIV treatment and pain management. Frontier Biotech's first commercial product was approved by the National Medical Product Administration (NMPA), which is the counterpart of the Food and Drug Administration (FDA) in China, in May 2018 through a priority review process and has gained accelerated approval. Two additional drug candidates are currently undergoing multiple clinical trials in Phase I and Phase II in both China and the United States. Frontier Biotech brings together many of the best scholars, scientists, and professionals in R&D, senior management, marketing, international business development, and manufacturing. At Frontier Biotech, their long-standing commitment to excellence is in everything they do throughthe entire development cycle from drug discovery, preclinical research to global clinical development. This approach has enabled Frontier Biotech to emerge in the global market as a competitive player in the field of HIV long-acting treatment and immunotherapy.